World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
23899
World Ranking
17991
National Ranking
727

Sabino De Placido publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sabino De Placido sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 449 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sabino De Placido D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sabino De Placido sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sabino De Placido is affiliated with the University of Naples Federico II in Italy. Their research contributions span multiple areas within Medicine, with particular emphasis on Oncology and related fields. They have authored a significant body of work in the domains of Biochemistry, Genetics and Molecular Biology.

The main fields of study covered in their publications include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader fields, their subfields of specialization are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Neurology
  • Surgery

The primary research topics addressed in their work encompass:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Myasthenia Gravis and Thymoma
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer

Some of the recent published papers include:

  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer (2021, Annals of Oncology)
  • Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (2021, npj Breast Cancer)
  • Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial (2022, Journal of Clinical Oncology)
  • HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis (2020, Cancer Treatment Reviews)
  • Toll-Like Receptors and COVID-19: A Two-Faced Story with an Exciting Ending (2020, Future Science OA)

The venues frequently chosen for publication reflect the scientist's research focus and include:

  • Annals of Oncology
  • Mediastinum
  • ESMO Open
  • Journal of Clinical Oncology
  • Cancers

Frequent co-authors in their publications are:

  • Pietro De Placido
  • Grazia Arpino
  • Mario Giuliano
  • Lucia Del Mastro
  • Erica Pietroluongo

Best Publications

  • A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

    Giuseppe Manghisi;Silvana Elba;Ascanio Mossa;Antonio Giorgio

  • Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,

    Fortunato Ciardiello;Rosa Caputo;Roberto Bianco;Vincenzo Damiano

  • Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80)

    Izzo Francesco;Oreste Cuomo;Gaetano Capuano;Giuseppe Ruggiero

  • Estrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance

    Grazia Arpino;Heidi Weiss;Adrian V. Lee;Rachel Schiff

  • Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer

    Giuseppe Di Lorenzo;Giampaolo Tortora;Francesco P. D’Armiento;Gaetano De Rosa

  • Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer : A Meta-Analysis of Randomized Trials

    Michele De Laurentiis;Giuseppe Cancello;Diego D'Agostino;Mario Giuliano

  • Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

    Massimo Di Maio;Ciro Gallo;Natasha B. Leighl;Maria Carmela Piccirillo

  • Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

    Fortunato Ciardiello;Roberto Bianco;Roberta Caputo;Rosa Caputo

  • Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

    Francesco Schettini;Francesco Schettini;Nuria Chic;Nuria Chic;Fara Brasó-Maristany;Fara Brasó-Maristany;Laia Paré

  • Antitumor Activity of Sequential Treatment with Topotecan and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225

    Fortunato Ciardiello;Roberto Bianco;Vincenzo Damiano;Sonya De Lorenzo

  • A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

    Michele De Laurentiis;Grazia Arpino;Grazia Arpino;Erminia Massarelli;Angela Ruggiero

  • Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

    Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

  • Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

    Mario Giuliano;Mario Giuliano;Mario Giuliano;Antonio Giordano;Antonio Giordano;Summer Jackson;Kenneth R Hess

  • Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

    Antonio Giordano;Hui Gao;Simone Anfossi;Evan Cohen

  • Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy

    Grazia Arpino;Carolina Gutierrez;Heidi Weiss;Mothaffar Rimawi

  • Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

    Mario Giuliano;Anum Shaikh;Hin Ching Lo;Grazia Arpino

  • Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

    Giampaolo Tortora;Rosa Caputo;Vincenzo Damiano;Davide Melisi

  • First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial

    Mothaffar Rimawi;Jean-Marc Ferrero;Juan de la Haba-Rodriguez;Christopher Poole

  • Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

    Cataldo Bianco;Roberto Bianco;Giampaolo Tortora;Vincenzo Damiano

Frequent Co-Authors

Riccardo Autorino
Riccardo Autorino Virginia Commonwealth University
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Giampaolo Tortora
Giampaolo Tortora University of Verona
Francesco Cognetti
Francesco Cognetti Sapienza University of Rome
Stefano Pepe
Stefano Pepe University of Salerno
Sandro Pignata
Sandro Pignata National Cancer Institute
Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Antonio Giordano
Antonio Giordano Temple University
Pierfranco Conte
Pierfranco Conte University of Padua
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have a variety of online degree options that can support many career pathways beyond traditional medicine. For those interested in advancing nursing practice, there are many cheapest dnp programs online, making doctoral-level education more accessible and affordable.

Registered nurses seeking career advancement can pursue the rn to bsn cheapest programs, perfect for building critical skills and boosting job opportunities without a heavy financial burden.

For those who hold a non-nursing bachelor’s degree but want to transition into the nursing field, direct entry msn programs for non-nurses online offer a shortcut to becoming an advanced practice nurse in less time.

Additionally, students looking for a faster route into healthcare may benefit from online adn programs, which provide an accessible path to becoming a registered nurse.

Exploring these online degrees can open doors to a wide range of healthcare careers, offering flexibility and affordability for diverse student needs.

Best Scientists Citing Sabino De Placido

Trending Scientists

Recently Published Articles